Iron Path Capital Names Jake Fitzgerald as New CEO of PureTech Scientific

Appointment taps industry leader who brings decades of knowledge to drive continued growth and success

Iron Path Capital (Iron Path), a private equity firm focused on healthcare and specialty industrials, today announced the appointment of industry veteran Jake Fitzgerald as Chief Executive Officer of PureTech Scientific LLC (PureTech), a global leader in glycolic acid synthesis and technology. PureTech was founded by Iron Path after acquiring the Glycolic Acid business from The Chemours Company last August.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819522920/en/

Iron Path Capital names Jake Fitzgerald as the new CEO of PureTech Scientific. (Photo: Business Wire)

Iron Path Capital names Jake Fitzgerald as the new CEO of PureTech Scientific. (Photo: Business Wire)

Fitzgerald most recently served as President of Americas Packaging at Essentra, where he had been promoted after a five year tenure as Regional Business Director. Prior to Essentra, Fitzgerald was Site Manager at Dow Chemical. His previous experience gives him a wealth of industry knowledge to guide PureTech into the next era of opportunities and success.

“Jake’s keen understanding of market trends and visionary leadership are exactly what PureTech needs to continue its trajectory of success,” said Scott Mraz, co-founder and managing partner of Iron Path. “We are confident that under his stewardship, Jake will empower the PureTech team to drive further innovation, create significant value for customers, and exceed our ambitious goals of setting new standards in our field.”

Fitzgerald’s appointment underscores Iron Path’s and PureTech’s shared commitment to innovation in the Life Sciences and Specialty Chemical industries. Under his leadership, PureTech is poised to solidify its position as an industry leader, providing ultra-high purity alpha hydroxy acids across the Life Science and Specialty chemical sectors.

“I am honored to join PureTech and excited about the journey ahead. With its strong foundation and commitment to innovation, PureTech is uniquely positioned to create a safer and healthier world with glycolic acid science,” said Fitzgerald. “I look forward to leading the talented team here to drive growth and continue pushing the boundaries of what’s possible to achieve the company’s full potential in this next chapter.”

About PureTech Scientific LLC

Headquartered in Belle, West Virginia, PureTech Scientific is the global leader in organic synthesis of ultra-high purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries, and the sole manufacturer in the Americas. With over 85 years of operating experience and a commitment to reducing our carbon footprint, we are dedicated to delivering world-class products, innovations and customer support for a healthier and safer world.

www.puretechscientific.com

About Iron Path Capital

Iron Path Capital is an operationally focused private equity firm focused on lower-middle-market investments across the healthcare and specialty industrial sectors. With offices in Nashville, TN and Charlottesville, VA, Iron Path Capital supports its partners with capital, operating expertise, business development, and industry relationships to achieve significant scale. Iron Path Capital selects companies with stable cash flows, superior management teams, strong performance trajectories, and multiple vectors for growth, both organic and through consolidation.

Learn more at www.ironpathcapital.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.